April 15, 2025 03:42 PM EDT

Leqembi wins EU authorization for some Alzheimer's patients, giving Biogen, Eisai a boost over Lilly

Nicole DeFeudis

Editor

European regulators on Tuesday authorized the use of Biogen and Eisai’s Alzheimer’s treatment Leqembi for some early-stage patients “under strict conditions.”

The decision from the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Leqembi wins EU authorization for some Alzheimer's patients, giving Biogen, Eisai a boost over Lilly

Nicole DeFeudis

Editor

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Trump pledges his support for a change to the IRA long sought by drugmakers

J&J's Duato says 'not tariffs, but tax policy' is best way to boost US manufacturing

Pharma tariffs could leave little room to hide with sweeping probe underway

Sanofi’s Kymab-originated inflammatory drug flunks mid-stage asthma trial

Exclusive: A small biotech will bring Roche's Angelman drug back to life

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

Leqem­bi wins EU au­tho­riza­tion for some Alzheimer's pa­tients, giv­ing Bio­gen, Ei­sai a boost over Lil­ly

Editor

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Leqembi wins EU authorization for some Alzheimer's patients, giving Biogen, Eisai a boost over Lilly